Gao Lin Investment increased its holdings of Jianshi Technology-B (09877) by 20.85 million shares, accounting for about 5% of the total number of shares

The Zhitong Finance App learned that according to the latest data from the Hong Kong Stock Exchange, Hillhouse Fund V, L.P. (Phase V) increased its holdings of Jianshi Technology-B (09877) by 20.85 million shares, accounting for about 5% of the total number of shares.

Since the beginning of the year, Jianshi Technology's transcatheter aortic prosthetic valve system KEN-Valve has been approved for marketing by NMPA and commercial implantation has begun nationwide; clinical data from the global multi-center clinical trial of the transcatheter tricuspid valve replacement system Lux-Valve Plus and its excellent use results in large valve ring patient groups were published on EUROPCR and New York Valves, respectively; one-year clinical data of the transcatheter mitral valve repair clip system JensClip were published on EUROPCR. The company has made significant progress on the TAVR, TTVR and TMVR tracks, and the global commercialization process is progressing steadily.

The transaction involved other related parties: Hillhouse Investment Management V, L.P., Hillhouse Investment Management, Ltd., and TNY Holdings Limited.